IELTS Academic Reading Practice 72

 
schedule First Time: 0 min 0 secs
replay Retake Test
  • Your Score: /
schedule20:00
This reading practice simulates one part of the IELTS Academic Reading test. You should spend about twenty minutes on it. Read the passage and answer questions 27-40.

Questions 27-33

Look at the following Statements (Questions 27-33) and The list of people or organization below.

Match each statement with the correct person or organization A-D.

Write the correct number A-F in boxes Questions 27-33 on your answer sheet.

NB You may use any letter more than once.

The list of people or organization
  1. Richard Mawle
  2. The Children Accident Prevention Trust
  3. Thea Swayne
  4. Karel van der Waarde
  5. Roger Coleman
  6. Hugo Glover

27. Explains that the majority of child poisonings were due to the misapplication of medication
28. Is disparaging about the layout and ordering of important product information
29. Argues that packaging should be made to overcome difficult situations in which it may be used
30. Conducted research on how easy it is to read information on leaflets and packaging
31. Refers to serious medical errors arising due to poor labelling
32. Believes that reasoning ability should be a factor in medical packaging design
33. Governing bodies should investigate many different container cases rather than individual ones.
Questions 34-36

Choose three letters A-F.

Write your answers in boxes 34-36 on your answer sheet.

Which three statements are correct regarding designs for over the counter medicines?
  1. commissioned by design agencies
  2. generic company designs
  3. tested on consumer groups
  4. attractiveness and ability to tell them apart are significant
  5. are created by an in-house team
  6. not much time spent on these designs

34
35
36
Questions 37-40

Complete the summary below.  

Choose NO MORE THAN THREE WORDS from the passage for each answer.
Write your answers in 37-40 on your answer sheet.

EU rules expect PILS to be easily read and simple to use. Therefore, pharmaceutical companies will need to begin to ensure that packaging is intelligible and simple to use. Results from this research will be used to change packaging designs and the materials used. When testing a new design, a group is usually shown the material to check whether it is easily understood. Changes are made using the results of this and finally, another group is consulted to ensure that there has been an , although this has been criticized as being done out of context. At a trade exhibition designs for several whose purpose is to help users, were previewed. Robert Coleman believes that design should be based on ease of use and not be just be , saying instead that it should be used to create a basic standard and provide new ideas.


Answer Sheet
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
N/A
16
N/A
17
N/A
18
N/A
19
N/A
20
N/A
21
N/A
22
N/A
23
N/A
24
N/A
25
N/A
26
N/A
27
N/A
28
N/A
29
N/A
30
N/A
31
N/A
32
N/A
33
N/A
34
N/A
35
N/A
36
N/A
37
N/A
38
N/A
39
N/A
40
N/A


  • help Learn how to HIGHLIGHT & ADD NOTES
    1. HOLD LEFT CLICK
    2. DRAG MOUSE OVER TEXT
    3. RIGHT CLICK SELECTED TEXT

Improving Patient Safety

Some of the most prominent design issues in pharmaceuticals are drag packaging and patient information leaflets (PILS). Many letters have appeared in medical journals’ over the years from pharmacists dismayed at the designs of packaging that are “accidents waiting to happen.” Packaging design in the pharmaceutical industry is handled by either in-house teams or design agencies. Designs for over-the-counter medicines, where characteristics such as attractiveness and distinguishability are regarded as significant, are usually commissioned from design agencies. A marketing team will prepare a brief, and the designers will come up with perhaps six or seven designs. These are whittled down to two or three that might be tested on a consumer group. In contrast, most designs for prescription-only products are created in-house. In some cases, this may simply involve applying a company’s house design (ie, logo, color, font, etc). The chosen design is then handed over to design engineers who work out how the packaging will be produced.

The author of the recently published “Information design for patient safety,” Thea Swayne, tracked the journey of  medicine from manufacturing plant, through distribution warehouses, pharmacies and hospital wards, to patients’ homes. Her book highlights a multitude of design problems with current packaging, such as lookalikes and soundalikes, small type sizes and glares on blister foils. Situations in which medicines are used include a parent giving a cough medicine to a child in the middle of the night and a busy pharmacist selecting one box from hundreds. It is argued that packaging should be designed for moments such as these. “Manufacturers are not aware of the complex situations into which products go. As designers, we are interested in not what is supposed to happen in [hospital] wards, but what happens in the real world,” Ms. Swayne said. Incidents where someone’s vein has been injected intrathecally instead of spine are a classic example of how poor design can contribute to harm. Investigations following these tragedies have attributed some blame to poor typescript.

Child protection is another area that gives designers opportunities to improve safety. According to the Child Accident Prevention Trust, seven out of ten children admitted to hospital with suspected poisoning have swallowed medicine. Although child-resistant closures have reduced the number of incidents, they are not fully child-proof. The definition of such a closure is one that not more than 15 percent of children aged between 42 and 51 months can open within five minutes. There is scope for improving what is currently available, according to Richard Mawle, a freelance product designer. “Many child-resistant packs are based on strength. They do not necessarily prevent a child from access, but may prevent people with a disability,” he told The Journal. “The legal requirements are there for a good reason, but they are not good enough in terms of the users,” he said. “Older people, especially those with arthritis, may have the same level of strength as a child,” he explained, and suggested that better designs could rely on cognitive skills (eg. making the opening of a container a three-step process) or be based on the physical size of hands.

Mr. Mawle worked with GlaxoSmithKline on a project to improve compliance through design, which involved applying his skills to packaging and PILs. Commenting on the information presented, he said, “There can be an awful lot of junk at the beginning of PILs. For example, why are company details listed towards the beginning of a leaflet when what might be more important for the patient is that the medicine should not be taken with alcohol?”

Lookalike boxes present a potential for picking errors and an obvious solution would be to use colors to highlight different strengths. However, according to Ms. Swayne, color differentiation needs to be approached with care. Not only should strong color contrasts be used but designating a color to a particular strength (color coding) is not recommended because this could lead to the user not reading the text on a box.

Design features can provide the basis for lengthy debates. For example, one argument is that if all packaging is white with black lettering, people would have no choice but to read every box carefully. The problem is that trials of drug packaging design are few, while common studies of legibility and comprehensibility usually concern road traffic signs and visual display units. Although some designers take results from such studies into account, proving that a particular feature is beneficial can be difficult. For example, EU legislation requires that packaging must now include the name of the medicine in Braille but, according to Karel van der Waarde, a design consultant to the pharmaceutical industry, “it is not known how much visually impaired patients will benefit, nor how much the reading of patients without visual impairments will be impaired.”

More evidence might, however, soon be available. EU legislation requires PILs to reflect consultations with target patient groups to ensure they are legible, clear and easy to use. This implies that industry will have to start conducting tests. Dr. van der Waarde has performed readability studies on boxes and PILs for industry. A typical study involves showing a leaflet or package to a small group and asking them questions to test understanding. Results and comments are used to modify the material, which is then tested on a larger group. A third group is used to show that any further changes made are an improvement. Dr. van der Waarde is, however, skeptical about the legal requirements and says that many regulatory authorities do not have the resources to handle packaging information properly. “They do not look at the use of packaging in a practical context. They only see one box at a time and not several together as pharmacists would do,” he said.

The RCA innovation exhibition this year revealed designs for a number of innovative objects. “The popper,” made by Hugo Glover, aims to help arthritis sufferers remove tablets from blister packs, and “pluspoint,” created by James Cobb, is an adrenaline auto-injector that aims to overcome the fact that many patients do not carry their auto-injectors due to their prohibitive size. The aim of good design, according Roger Coleman, professor of inclusive design at the RCA, is to try to make things more user-friendly as well as safer. Surely, in a patient-centered health system, that can only be a good thing. “Information design for patient safety” is not intended to be mandatory. Rather, its purpose is to create a basic design standard and to stimulate innovation. The challenge for the pharmaceutical industry, as a whole, is to adopt such a standard.

Reading Passage Vocabulary
Improving Patient Safety

Some of the most prominent design issues in pharmaceuticals are drag packaging and patient information leaflets (PILS). Many letters have appeared in medical journals’ over the years from pharmacists dismayed at the designs of packaging that are “accidents waiting to happen.” Packaging design in the pharmaceutical industry is handled by either in-house teams or design agencies. Designs for over-the-counter medicines, where characteristics such as attractiveness and distinguishability are regarded as significant, are usually commissioned from design agencies. A marketing team will prepare a brief, and the designers will come up with perhaps six or seven designs. These are whittled down to two or three that might be tested on a consumer group. In contrast, most designs for prescription-only products are created in-house. In some cases, this may simply involve applying a company’s house design (ie, logo, color, font, etc). The chosen design is then handed over to design engineers who work out how the packaging will be produced.

The author of the recently published “Information design for patient safety,” Thea Swayne, tracked the journey of  medicine from manufacturing plant, through distribution warehouses, pharmacies and hospital wards, to patients’ homes. Her book highlights a multitude of design problems with current packaging, such as lookalikes and soundalikes, small type sizes and glares on blister foils. Situations in which medicines are used include a parent giving a cough medicine to a child in the middle of the night and a busy pharmacist selecting one box from hundreds. It is argued that packaging should be designed for moments such as these. “Manufacturers are not aware of the complex situations into which products go. As designers, we are interested in not what is supposed to happen in [hospital] wards, but what happens in the real world,” Ms. Swayne said. Incidents where someone’s vein has been injected intrathecally instead of spine are a classic example of how poor design can contribute to harm. Investigations following these tragedies have attributed some blame to poor typescript.

Child protection is another area that gives designers opportunities to improve safety. According to the Child Accident Prevention Trust, seven out of ten children admitted to hospital with suspected poisoning have swallowed medicine. Although child-resistant closures have reduced the number of incidents, they are not fully child-proof. The definition of such a closure is one that not more than 15 percent of children aged between 42 and 51 months can open within five minutes. There is scope for improving what is currently available, according to Richard Mawle, a freelance product designer. “Many child-resistant packs are based on strength. They do not necessarily prevent a child from access, but may prevent people with a disability,” he told The Journal. “The legal requirements are there for a good reason, but they are not good enough in terms of the users,” he said. “Older people, especially those with arthritis, may have the same level of strength as a child,” he explained, and suggested that better designs could rely on cognitive skills (eg. making the opening of a container a three-step process) or be based on the physical size of hands.

Mr. Mawle worked with GlaxoSmithKline on a project to improve compliance through design, which involved applying his skills to packaging and PILs. Commenting on the information presented, he said, “There can be an awful lot of junk at the beginning of PILs. For example, why are company details listed towards the beginning of a leaflet when what might be more important for the patient is that the medicine should not be taken with alcohol?”

Lookalike boxes present a potential for picking errors and an obvious solution would be to use colors to highlight different strengths. However, according to Ms. Swayne, color differentiation needs to be approached with care. Not only should strong color contrasts be used but designating a color to a particular strength (color coding) is not recommended because this could lead to the user not reading the text on a box.

Design features can provide the basis for lengthy debates. For example, one argument is that if all packaging is white with black lettering, people would have no choice but to read every box carefully. The problem is that trials of drug packaging design are few, while common studies of legibility and comprehensibility usually concern road traffic signs and visual display units. Although some designers take results from such studies into account, proving that a particular feature is beneficial can be difficult. For example, EU legislation requires that packaging must now include the name of the medicine in Braille but, according to Karel van der Waarde, a design consultant to the pharmaceutical industry, “it is not known how much visually impaired patients will benefit, nor how much the reading of patients without visual impairments will be impaired.”

More evidence might, however, soon be available. EU legislation requires PILs to reflect consultations with target patient groups to ensure they are legible, clear and easy to use. This implies that industry will have to start conducting tests. Dr. van der Waarde has performed readability studies on boxes and PILs for industry. A typical study involves showing a leaflet or package to a small group and asking them questions to test understanding. Results and comments are used to modify the material, which is then tested on a larger group. A third group is used to show that any further changes made are an improvement. Dr. van der Waarde is, however, skeptical about the legal requirements and says that many regulatory authorities do not have the resources to handle packaging information properly. “They do not look at the use of packaging in a practical context. They only see one box at a time and not several together as pharmacists would do,” he said.

The RCA innovation exhibition this year revealed designs for a number of innovative objects. “The popper,” made by Hugo Glover, aims to help arthritis sufferers remove tablets from blister packs, and “pluspoint,” created by James Cobb, is an adrenaline auto-injector that aims to overcome the fact that many patients do not carry their auto-injectors due to their prohibitive size. The aim of good design, according Roger Coleman, professor of inclusive design at the RCA, is to try to make things more user-friendly as well as safer. Surely, in a patient-centered health system, that can only be a good thing. “Information design for patient safety” is not intended to be mandatory. Rather, its purpose is to create a basic design standard and to stimulate innovation. The challenge for the pharmaceutical industry, as a whole, is to adopt such a standard.

 
IELTS Academic Reading Tips for Success
These are general tips that will appear on all reading questions.

coming soon

 
close
Hi, there!

Create your free beta account to use this feature.

close
Create your free beta account